Theriva Biologics (DB:SFY0) - 주가, 뉴스 및 분석

SFY0 주식 개요

는 미국에서 미충족 수요가 높은 분야의 암 및 관련 질병을 치료하는 치료제를 개발하는 임상 단계 회사입니다. 자세한 내용

SFY0 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	3/6
배당금	0/6

위험 분석

의미 있는 시가총액이 없습니다. ( €3M )

수익은 향후 3년간 연평균 8.9% 씩 감소할 것으로 예상됩니다.

수익이 1백만 달러 미만인 경우 ( $0 )

지난 1년 동안 주주가 크게 희석되었습니다.

+ 3 더 많은 위험

Theriva Biologics, Inc. 경쟁사

bioXXmed

XTRA:T5O

€1.4m

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€22.6m

4SC

DB:VSC

€49.1m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Theriva Biologics
과거 주가
현재 주가	US$2.42
52주 최고치	US$14.00
52주 최저치	US$2.42
베타	1.34
11개월 변경	0%
3개월 변경 사항	-0.82%
1년 변경 사항	-75.92%
33년 변화	-96.47%
5년 변화	-97.21%
IPO 이후 변화	-99.99%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	SFY0	DE Biotechs	DE 마켓
7D	0%	-0.7%	-0.02%
1Y	-75.9%	-17.2%	8.2%

수익률 대 산업: SFY0 지난 1년 동안 -17.2 %를 반환한 German Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: SFY0 지난 1년 동안 8.2 %를 반환한 German 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is SFY0's price volatile compared to industry and market?
SFY0 volatility
SFY0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

안정적인 주가: SFY0 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: 지난 1년간 SFY0 의 변동성 변화를 확인하기에는 데이터가 충분하지 않습니다.

회사 소개

설립	직원	CEO	웹사이트
n/a	22	Steve Shallcross	therivabio.com

임상 단계 회사인 Theriva Biologics는 미국에서 미충족 수요가 높은 분야의 암 및 관련 질병을 치료하는 치료제를 개발하는 회사입니다. 이 회사의 주요 제품 후보로는 췌장암 치료를 위한 임상 2상 연구, 망막모세포종 치료를 위한 임상 1상 연구, 두경부 편평세포암 치료를 위한 임상 1상 연구, 고형 종양 치료를 위한 임상 1상 연구를 진행 중인 종양 용해성 인간 아데노바이러스인 VCN-01이 있습니다. 또한 고형 종양 치료를 위한 VCN-11, 클로스트리디오데스 디피실 감염 및 반코마이신 내성 장구균과 같은 병원성 유기체의 과증식 및 감염을 예방하기 위해 위장관에서 일반적으로 사용되는 다양한 정맥 내 베타락탐 항생제를 분해하고 동종 조혈모세포 이식 수혜자의 급성 이식편대숙주병(aGVHD) 발생 및 중증도를 감소시키는 마이크로바이옴 손상 방지용 SYN-004를 개발 중입니다; 장내 알칼리성 포스파타제 효소 재조합 경구용 제제인 SYN-020은 국소 위장관 질환과 전신 질환을 모두 치료할 수 있습니다.

Theriva Biologics, Inc. 기본 사항 요약

Theriva Biologics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
SFY0 기본 통계
시가총액	€2.70m
수익(TTM)	-€25.21m
수익(TTM)	n/a

0.0x

P/S 비율

-0.1x

P/E 비율

SFY0 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
SFY0 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$26.69m
수익	-US$26.69m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-11.75
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0.7%

SFY0 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

SFY0 주식 개요

위험 분석

Theriva Biologics, Inc. 경쟁사

XTRA:T5O

€1.4m

XTRA:CNW

€6.5m

XTRA:MDG1

€22.6m

DB:VSC

€49.1m

가격 내역 및 성능

최근 뉴스 및 업데이트

Theriva Biologics, Inc. Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics, Inc. Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics, Inc., Annual General Meeting, Oct 31, 2024

High number of new and inexperienced directors

Theriva Biologics, Inc. has filed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

Recent updates

Theriva Biologics, Inc. Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics, Inc. Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics, Inc., Annual General Meeting, Oct 31, 2024

High number of new and inexperienced directors

Theriva Biologics, Inc. has filed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

New major risk - Financial position

Theriva Biologics, Inc. Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation

Theriva Biologics, Inc. has filed a Follow-on Equity Offering in the amount of $1.235303 million.

Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Theriva Biologics, Inc. Announces Presentation at Esmo Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating Vcn-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Theriva Biologics, Inc., Annual General Meeting, Oct 02, 2023

New minor risk - Shareholder dilution

New major risk - Market cap size

Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery

Theriva Biologics, Inc. Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics, Inc. Announces First Patient Dosed in VIRAGE, A Phase 2B Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors

High number of new and inexperienced directors

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004

Theriva Biologics, Inc. Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics, Inc., Annual General Meeting, Sep 30, 2022

Synthetic Biologics, Inc. announced that it expects to receive $3 million in funding from MSD Partners, L.P.

Synthetic Biologics, Inc. Notifies Clearance of Safety Evaluation Period

High number of new and inexperienced directors

Synthetic Biologics, Inc. Reports Positive Safety Data on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

Synthetic Biologics, Inc. Announces Peer-Reviewed Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients with Advanced Solid Tumors

Synthetic Biologics, Inc. (NYSEAM:SYN) signed a definitive agreement to acquire VCN Biosciences SL from Grifols Innovation and New Technologies Limited and others for $85.6 million.

Synthetic Biologics Provides Update on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

Synthetic Biologics, Inc. Announces Clinical Development and Operational Update

Insider recently bought €144k worth of stock

Synthetic Biologics, Inc. to Report Fiscal Year 2020 Results on Mar 04, 2021

New 90-day high: €1.23

Synthetic Biologics, Inc. Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol

Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American

Synthetic Biologics, Inc. Announces Executive Changes

Synthetic Biologics, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: €0.23

New 90-day low: €0.24

Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2B Clinical Study of SYN-010 in IBS-C Patients

New 90-day low: €0.37

New 90-day high - €0.59

Synthetic Biologics, Inc. to Report Q2, 2020 Results on Aug 06, 2020

주주 수익률

가격 변동성

회사 소개

Theriva Biologics, Inc. 기본 사항 요약

0.0x

-0.1x

수익 및 수익